Table 1. Participant Demographic Characteristics and Baseline Features.
| Characteristic | Complete Cohort (n = 94) | Placebo (n = 49) | Pregnenolone (n = 45) |
|---|---|---|---|
| Age, mean (SD), y | 37.52 (9.84) | 37.55 (10.25) | 37.48 (9.47) |
| Sex, No. (%) | |||
| Female | 10 (10.6) | 5 (50.0) | 5 (50.0) |
| Male | 84 (89.4) | 44 (52.4) | 40 (47.6) |
| Race/ethnicity, No. (%) | |||
| Caucasian | 53 (56.4) | 29 (54.7) | 24 (45.3) |
| African American | 31 (33.0) | 16 (51.6) | 15 (48.4) |
| Other | 10 (10.6) | 4 (40.0) | 6 (60.0) |
| Pretreatment pain intensity measures, mean (SD) | |||
| Pain intensity (diary) | 5.03 (1.55) | 4.83 (1.60) | 5.24 (1.48) |
| Pain recall | 4.95 (1.59) | 4.78 (1.66) | 5.15 (1.51) |
| Pain intensitya | 4.79 (1.54) | 4.51 (1.39) | 5.09 (1.66) |
| Pretreatment pain interference measures, mean (SD) | |||
| Average interferencea | 2.89 (2.35) | 2.49 (2.19) | 3.33 (2.46) |
| Activity | 3.35 (2.53) | 2.78 (2.35) | 3.98 (2.61) |
| Mood | 2.79 (2.54) | 2.47 (2.49) | 3.13 (2.58) |
| Walking | 2.80 (2.54) | 2.29 (2.36) | 3.36 (2.64) |
| Work | 3.15 (2.63) | 2.61 (2.40) | 3.73 (2.77) |
| Relations | 1.89 (2.35) | 1.41 (2.02) | 2.42 (2.59) |
| Sleep | 3.52 (2.94) | 3.43 (2.84) | 3.62 (3.07) |
| Enjoyment | 2.76 (2.70) | 2.47 (2.51) | 3.07 (2.90) |
a
Measured using the Brief Pain Inventory.